Biovac Nets $108M for A Full-Cycle Vaccine Plant
💉 Meet Biovac
-
Biovac is a South African biopharmaceutical firm that develops and makes vaccines specifically for the continent.
-
They just secured a $108M finance package to expand their infrastructure.
-
Investor check. The International Finance Corporation and the European Investment Bank led the funding. The European Commission also joined the group to support the expansion.
🏗️ Building From Scratch
-
Right now, Africa imports about 99% of its vaccines for a population of 1.4 billion people. This often leads to supply shortages during health crises.
-
Biovac is building a facility in Cape Town that handles the whole process, from making the raw drug substance to final packaging.
-
The 15,000 square meter plant will produce mRNA and microbial-based vaccines locally.
-
It is the first site on the continent capable of this end-to-end production.
📈 Why This Matters
-
This project is a shift toward local medical independence. Moving production to Cape Town reduces the reliance on global supply chains that often fail during pandemics.
-
The company has partnered with global health organizations to ensure the new plant meets international technical standards.
🔝 Looking Ahead
-
The $108M will be used to buy high-end manufacturing equipment and finish the construction of the new site.
-
The expansion will double the current production capacity for the company.
-
It will also create more than 200 high-skilled jobs in the pharmaceutical sector in South Africa.